TITLE

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection

AUTHOR(S)
Lyseng-Williamson, Katherine A.; Scott, Lesley J.
PUB. DATE
October 2012
SOURCE
Clinical Drug Investigation;2012, Vol. 32 Issue 10, p715
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Evipleraâ„¢ [EU]; Compleraâ„¢ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient population, rilpivirine plus emtricitabine/tenofovir disoproxil fumarate was noninferior to efavirenz plus emtricitabine/tenofovir disoproxil fumarate in terms of reducing viral HIV-1 RNA level to <50 copies/mL and was generally better tolerated than efavirenz plus emtricitabine/tenofovir disoproxil fumarate.
ACCESSION #
82156147

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics